Eventide Asset Management - Q3 2014 holdings

$716 Million is the total value of Eventide Asset Management's 103 reported holdings in Q3 2014. The portfolio turnover from Q2 2014 to Q3 2014 was 6.7% .

 Value Shares↓ Weighting
MDVN  MEDIVATION INC$27,219,000
+28.3%
275,3000.0%3.80%
+31.7%
AGIO SellAGIOS PHARMACEUTICALS INC$26,479,000
+17.8%
431,600
-12.0%
3.70%
+21.0%
PANW  PALO ALTO NETWORKS INC$20,169,000
+17.0%
205,6000.0%2.82%
+20.1%
TRW  TRW AUTOMOTIVE HLDGS CORP$20,088,000
+13.1%
198,4000.0%2.80%
+16.1%
ABBV BuyABBVIE INC$19,101,000
+15.6%
330,700
+13.0%
2.67%
+18.7%
CELG  CELGENE CORP$18,008,000
+10.4%
190,0000.0%2.51%
+13.3%
MIC  MACQUARIE INFRASTR CO LLCmembership int$17,022,000
+6.9%
255,2000.0%2.38%
+9.8%
LOW BuyLOWES COS INC$16,172,000
+39.0%
305,600
+26.1%
2.26%
+42.7%
RHT  RED HAT INC$15,026,000
+1.6%
267,6000.0%2.10%
+4.3%
LYB BuyLYONDELLBASELL INDUSTRIES N$14,550,000
+30.8%
133,900
+17.6%
2.03%
+34.3%
EOG  EOG RES INC$14,338,000
-15.3%
144,8000.0%2.00%
-13.0%
MGA  MAGNA INTL INC$14,208,000
-11.9%
149,7000.0%1.98%
-9.5%
BLUE BuyBLUEBIRD BIO INC$14,198,000
+378.7%
395,700
+414.6%
1.98%
+391.8%
LEA  LEAR CORP$13,903,000
-3.3%
160,9000.0%1.94%
-0.7%
SUNEQ  SUNEDISON INC$13,765,000
-16.5%
729,1000.0%1.92%
-14.2%
DYAX  DYAX CORP$13,464,000
+5.4%
1,330,4000.0%1.88%
+8.2%
MEOH  METHANEX CORP$13,447,000
+8.1%
201,3000.0%1.88%
+11.0%
WBC  WABCO HLDGS INC$13,379,000
-14.9%
147,1000.0%1.87%
-12.6%
LLTC  LINEAR TECHNOLOGY CORP$12,989,000
-5.7%
292,6000.0%1.81%
-3.2%
CPN BuyCALPINE CORP$12,970,000
+14.2%
597,700
+25.3%
1.81%
+17.2%
DATA BuyTABLEAU SOFTWARE INCcl a$12,358,000
+15.4%
170,100
+13.3%
1.72%
+18.5%
SYNA BuySYNAPTICS INC$11,741,000
-11.9%
160,400
+9.0%
1.64%
-9.6%
WAB  WABTEC CORP$11,726,000
-1.9%
144,7000.0%1.64%
+0.7%
CMRX  CHIMERIX INC$11,562,000
+25.9%
418,6000.0%1.61%
+29.2%
CBI  CHICAGO BRIDGE & IRON CO N V$11,211,000
-15.2%
193,8000.0%1.56%
-12.9%
CCI  CROWN CASTLE INTL CORP$10,525,000
+8.4%
130,7000.0%1.47%
+11.3%
ACAD  ACADIA PHARMACEUTICALS INC$10,478,000
+9.6%
423,2000.0%1.46%
+12.5%
STKL BuySUNOPTA INC$10,255,000
-12.7%
849,600
+1.8%
1.43%
-10.4%
IPHI BuyINPHI CORP$9,839,000
+5.7%
684,200
+7.9%
1.37%
+8.5%
PCYC  PHARMACYCLICS INC$9,700,000
+30.9%
82,6000.0%1.35%
+34.3%
TEX  TEREX CORP NEW$9,642,000
-22.7%
303,5000.0%1.35%
-20.6%
PTLA  PORTOLA PHARMACEUTICALS INC$9,414,000
-13.4%
372,4000.0%1.31%
-11.1%
CXP  COLUMBIA PPTY TR INC$9,400,000
-8.2%
393,8000.0%1.31%
-5.8%
ININ BuyINTERACTIVE INTELLIGENCE GRO$9,288,000
-10.2%
222,200
+20.6%
1.30%
-7.8%
ASML  ASML Holding NV$9,269,000
+5.9%
93,8000.0%1.29%
+8.7%
VMW  VMWARE INC$9,178,000
-3.1%
97,8000.0%1.28%
-0.5%
FPRX  FIVE PRIME THERAPEUTICS INC$9,074,000
-24.6%
773,6000.0%1.27%
-22.6%
VCYT BuyVERACYTE INC$8,941,000
+237.7%
917,000
+492.8%
1.25%
+246.7%
NVAX  NOVAVAX INC$7,959,000
-9.7%
1,908,7000.0%1.11%
-7.3%
CMRE  COSTAMARE INC$7,910,000
-5.8%
360,2000.0%1.10%
-3.3%
NRG  NRG ENERGY INC$7,724,000
-18.1%
253,4000.0%1.08%
-15.9%
STML BuySTEMLINE THERAPEUTICS INC$7,224,000
-12.0%
579,800
+3.6%
1.01%
-9.7%
LGND  LIGAND PHARMACEUTICALS INC$7,034,000
-24.6%
149,7000.0%0.98%
-22.6%
UFS SellDOMTAR CORP$6,977,000
-37.0%
198,600
-23.2%
0.97%
-35.4%
OII  OCEANEERING INTL INC$6,771,000
-16.6%
103,9000.0%0.94%
-14.4%
PWR  QUANTA SVCS INC$6,634,000
+5.0%
182,8000.0%0.93%
+7.7%
BWA  BORGWARNER INC$6,608,000
-19.3%
125,6000.0%0.92%
-17.1%
AYR  AIRCASTLE LTD$6,537,000
-7.9%
399,6000.0%0.91%
-5.5%
TSLA  TESLA MTRS INC$6,382,000
+1.1%
26,3000.0%0.89%
+3.7%
FC  FRANKLIN COVEY CO$6,183,000
-2.7%
315,6000.0%0.86%
-0.1%
KAR  KAR AUCTION SVCS INC$6,087,000
-10.2%
212,6000.0%0.85%
-7.7%
TTPH  TETRAPHASE PHARMACEUTICALS I$6,003,000
+47.9%
300,9000.0%0.84%
+51.8%
P103PS  NPS PHARMACEUTICALS INC$5,821,000
-21.3%
223,9000.0%0.81%
-19.2%
SRPT  SAREPTA THERAPEUTICS INC$5,467,000
-29.2%
259,1000.0%0.76%
-27.3%
SCTY  SOLARCITY CORP$5,304,000
-15.6%
89,0000.0%0.74%
-13.2%
SGMO  SANGAMO BIOSCIENCES INC$5,204,000
-29.4%
482,5000.0%0.73%
-27.4%
AZPN  ASPEN TECHNOLOGY INC$4,847,000
-18.7%
128,5000.0%0.68%
-16.5%
NLNK  NEWLINK GENETICS CORP$4,620,000
-19.3%
215,7000.0%0.64%
-17.2%
CGNX  COGNEX CORP$4,027,000
+4.9%
100,0000.0%0.56%
+7.7%
MGNX BuyMACROGENICS INC$3,992,000
+11.5%
191,000
+15.9%
0.56%
+14.4%
AGTC  APPLIED GENETIC TECHNOL CORP$3,824,000
-19.4%
205,5000.0%0.53%
-17.3%
CLDX  CELLDEX THERAPEUTICS INC NEW$3,742,000
-20.6%
288,7000.0%0.52%
-18.6%
AKBA  AKEBIA THERAPEUTICS INC$3,678,000
-20.4%
166,2000.0%0.51%
-18.2%
RARE  ULTRAGENYX PHARMACEUTICAL IN$2,977,000
+26.1%
52,6000.0%0.42%
+29.6%
CERN  CERNER CORP$2,317,000
+15.5%
38,9000.0%0.32%
+18.3%
ATRC  ATRICURE INC$2,242,000
-19.9%
152,3000.0%0.31%
-17.8%
SUPN BuySUPERNUS PHARMACEUTICALS INC$2,233,000
-15.3%
257,000
+6.8%
0.31%
-12.8%
NTUS  NATUS MEDICAL INC DEL$2,213,000
+17.3%
75,0000.0%0.31%
+20.7%
BMRN  BIOMARIN PHARMACEUTICAL INC$2,179,000
+16.0%
30,2000.0%0.30%
+18.8%
GWPH  GW PHARMACEUTICALS PLCads$2,021,000
-24.6%
25,0000.0%0.28%
-22.7%
RGEN  REPLIGEN CORP$1,979,000
-12.6%
99,4000.0%0.28%
-10.4%
CBST  CUBIST PHARMACEUTICALS INC$1,924,000
-5.0%
29,0000.0%0.27%
-2.2%
HPTX  HYPERION THERAPEUTICS INC$1,924,000
-3.4%
76,3000.0%0.27%
-0.7%
XLRN  ACCELERON PHARMA INC$1,878,000
-11.0%
62,1000.0%0.26%
-8.7%
SLXP SellSALIX PHARMACEUTICALS INC$1,844,000
-31.4%
11,800
-45.9%
0.26%
-29.8%
ARWR BuyARROWHEAD RESH CORP$1,694,000
+47.9%
114,700
+43.4%
0.24%
+51.9%
CEMP  CEMPRA INC$1,686,000
+2.2%
153,8000.0%0.24%
+4.9%
SAAS  INCONTACT INC$1,681,000
-5.3%
193,3000.0%0.24%
-2.9%
TGTX BuyTG THERAPEUTICS INC$1,654,000
+30.4%
155,000
+14.8%
0.23%
+34.3%
NBIX  NEUROCRINE BIOSCIENCES INC$1,514,000
+5.6%
96,6000.0%0.21%
+8.2%
ATHN  ATHENAHEALTH INC$1,462,000
+5.3%
11,1000.0%0.20%
+7.9%
SZYM SellSOLAZYME INC$1,417,000
-68.7%
190,000
-50.6%
0.20%
-67.9%
MEIP  MEI PHARMA INC$1,391,000
+8.8%
201,6000.0%0.19%
+11.5%
BRKR  BRUKER CORP$1,368,000
-23.7%
73,9000.0%0.19%
-21.7%
PCRX  PACIRA PHARMACEUTICALS INC$1,289,000
+5.5%
13,3000.0%0.18%
+8.4%
SAGE NewSAGE THERAPEUTICS INC$1,266,00040,200
+100.0%
0.18%
CSII  CARDIOVASCULAR SYS INC DEL$1,245,000
-24.2%
52,7000.0%0.17%
-22.0%
INSM  INSMED INC$1,156,000
-34.7%
88,6000.0%0.16%
-33.2%
FEIC  FEI CO$1,116,000
-16.9%
14,8000.0%0.16%
-14.8%
TNDM NewTANDEM DIABETES CARE INC$1,074,00080,000
+100.0%
0.15%
KPTI  KARYOPHARM THERAPEUTICS INC$1,048,000
-25.0%
30,0000.0%0.15%
-23.2%
OMED  ONCOMED PHARMACEUTICALS INC$1,000,000
-18.7%
52,8000.0%0.14%
-16.2%
MDSO  MEDIDATA SOLUTIONS INC$837,000
+3.5%
18,9000.0%0.12%
+6.4%
DRNA  DICERNA PHARMACEUTICALS INC$811,000
-43.6%
63,7000.0%0.11%
-42.3%
ACRX  ACELRX PHARMACEUTICALS INC$765,000
-46.5%
139,4000.0%0.11%
-44.8%
XOMA  XOMA Corp$746,000
-8.2%
177,2000.0%0.10%
-6.3%
AAVL NewAVALANCHE BIOTECHNOLOGIES IN$684,00020,000
+100.0%
0.10%
AEGR  AEGERION PHARMACEUTICALS INC$668,000
+4.0%
20,0000.0%0.09%
+6.9%
SNSS  SUNESIS PHARMACEUTICALS INC$655,000
+9.3%
91,8000.0%0.09%
+12.3%
TFX  TELEFLEX INC$609,000
-0.5%
5,8000.0%0.08%
+2.4%
QURE BuyUNIQURE NV$452,000
+54.8%
49,100
+128.7%
0.06%
+57.5%
RPTP  RAPTOR PHARMACEUTICAL CORP$387,000
-17.1%
40,4000.0%0.05%
-15.6%
VSTM  VERASTEM INC$178,000
-5.8%
20,9000.0%0.02%
-3.8%
AMBI ExitAMBIT BIOSCIENCES CORP$0-151,100
-100.0%
-0.14%
VSAR ExitVERSARTIS INC$0-50,000
-100.0%
-0.19%
SDRL ExitSEADRILL LIMITED$0-229,500
-100.0%
-1.25%
ROC ExitROCKWOOD HLDGS INC$0-170,400
-100.0%
-1.76%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2014-11-12
Signatures

The EDGAR filing(s) were signed by:

About Eventide Asset Management

Eventide Asset Management is a Boston-based investment firm that specializes in providing investment solutions to investors who are looking for long-term growth opportunities. The company was founded in 2008 by a group of experienced investment professionals who shared a common vision of creating a firm that would focus on investing in companies that are making a positive impact on society.

The company's investment philosophy is based on the belief that companies that are making a positive impact on society are more likely to be successful in the long run. Eventide's investment team conducts extensive research to identify companies that are aligned with this philosophy and have the potential to deliver strong returns over the long term.

The company's investment strategies are managed by a team of experienced professionals, including CEO Robin John, COO Finny Kuruvilla, and Chief Investment Officer, Dr. Finny Kuruvilla. The team has a proven track record of delivering strong returns to investors, and their investment strategies have been recognized by industry experts.

Eventide Asset Management offers a range of investment solutions, including mutual funds, separately managed accounts, and exchange-traded funds (ETFs). The company's funds are available to individual investors, financial advisors, and institutional investors.

Overall, Eventide Asset Management is a reputable investment firm that has a strong focus on investing in companies that are making a positive impact on society. The company's experienced investment team and proven track record make it a compelling option for investors who are looking for long-term growth opportunities.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
LOWES COS INC40Q3 20233.2%
PALO ALTO NETWORKS INC40Q3 20233.6%
ASML HOLDINGS NV40Q3 20231.9%
NEUROCRINE BIOSCIENCES INC40Q3 20231.1%
REPLIGEN CORP40Q3 20230.5%
VERACYTE INC38Q3 20231.5%
LAM RESEARCH CORP35Q3 20233.4%
XPO LOGISTICS INC34Q1 20233.8%
COLLEGIUM PHARMACEUTICAL INC34Q3 20232.6%
MAGNA INTL INC33Q4 20212.5%

View Eventide Asset Management's complete holdings history.

Latest significant ownerships (13-D/G)
Eventide Asset Management Q3 2014 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
Cogent Biosciences, Inc.February 14, 20232,589,7783.7%
ESSA Pharma Inc.Sold outFebruary 14, 202300.0%
Freeline Therapeutics Holdings plcFebruary 14, 20235,920,7659.1%
KnowBe4, Inc.Sold outFebruary 14, 202300.0%
Praxis Precision Medicines, Inc.February 14, 20233,518,0627.5%
Prometheus Biosciences, Inc.February 14, 20231,032,9382.2%
SUTRO BIOPHARMA, INC.Sold outFebruary 14, 202300.0%
Vital Farms, Inc.Sold outFebruary 14, 202300.0%
Zymeworks Inc.Sold outFebruary 14, 202300.0%
Entasis Therapeutics Holdings Inc.February 14, 2022590,6021.2%

View Eventide Asset Management's complete significant-ownership history.

Latest filings
TypeFiled
13F-HR/A2024-02-20
13F-HR2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14

View Eventide Asset Management's complete filings history.

Compare quarters

Export Eventide Asset Management's holdings